A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer
by Yash B. Shah, Amy L. Shaver, William Kevin Kelly, Grace Lu-Yao
IntroductionAbiraterone acetate and enzalutamide are commonly employed in prostate cancer therapy in an interchangeable manner. These drugs are highly efficacious in androgen antagonism to improve patient outcomes, but they also carry noteworthy risk of adverse effects. Common toxicities vary amongst the two drugs and may have differential interactions with patient co-morbidities, but these patterns are unclear as co-morbidities... Читать дальше...